Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and vomiting. The type of treatment for a patient suffering from mantle cell lymphoma depends on various factors such as the stage of disease, age, and overall health of the patient. In 2012, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy.
Rising prevalence of mantle cell lymphoma is expected to accelerate growth of the mantle cell lymphoma treatment market over the forecast period
Major factors driving growth of the mantle cell lymphoma market are rising prevalence of mantle cell lymphoma and increasing research and development activities in the healthcare sector resulting in a promising product pipeline. According to the study by Drug Development Technology, 2017, an estimated 3,300 new cases of mantle cell lymphoma are diagnosed every year in the U.S. The mantle cell lymphoma treatment market is expected to gain significant traction with the approval from the federal agencies. For instance, in October 2017, AstraZeneca received approval for Calquence under the FDA’s accelerated approval pathway for the treatment of adults with mantle cell lymphoma. Also, development of targeted agents with low toxicity profiles for the treatment of relapsed mantle cell lymphoma in combination with approved drugs is a major factor augmenting the mantle cell lymphoma treatment market growth. However, serious side effects of the drugs such as anemia, neutropenia, and diarrhea are the factors restraining growth of the mantle cell lymphoma treatment market.
The global mantle cell lymphoma treatment market is segmented on the basis of therapy type, route of administration, end user, and geography.
On the basis of therapy type, the global mantle cell lymphoma treatment market is segmented into:
- Monoclonal Antibody Therapy
- Targeted Therapy
- Stem Cell Treatment
On the basis of route of administration, the global mantle cell lymphoma treatment market is segmented into:
On the basis of end user, the global mantle cell lymphoma treatment market is segmented into:
- Ambulatory Surgical Centers
Accelerated approval pathway program by the U.S. FDA is expected to propel the mantle cell lymphoma treatment market in North America
Regional segmentation of the mantle cell lymphoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant in the global market over the forecast period. This is owing to increasing incidence rate of the disease in the region. According to the Leukemia and Lymphoma Society, 2014, about 70,800 new cases of cases of non-Hodkin Lymphoma were registered in the U.S., where mantle cell lymphoma represented about 6% or 4,200 cases of the total cases. Also, the FDA’s Center for Drug Evaluation and Research Agency works with manufacturers to analyze drug development, approval, promising the Breakthrough Therapy Destination Program to make treatments available for patients with rare disease. For instance, in 2013, the FDA approved Imbruvica (ibrutinib), manufactured by Janssen Pharmaceuticals, Inc. as a breakthrough therapy destination to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Asia Pacific is expected to witness high growth rate in the mantle cell lymphoma treatment market over the forecast period owing to rising government initiatives, rise in research and development to curb the disease.
Key players operating the market include:
Key players are offering products to cater to unmet needs in patients with relapsed or refractory mantle cell lymphoma. For instance, Kite Pharma, Inc. is focused on developing engineered autologous T cell therapy products for the treatment of cancer. In 2015, the company initiated Phase 2 clinical study of KTE-C19 in patients with relapsed or refractory mantle cell lymphoma.
Key players operating in the global mantle cell lymphoma treatment market include F.Hoffman La Roche Ltd., Abbvie, Inc., Kite Pharma, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., and Johnson and Johnson.